Changeflow GovPing Pharma & Drug Safety RIKEN Patent - Paraprevotella Bacterium Inhibit...
Routine Notice Added Final

RIKEN Patent - Paraprevotella Bacterium Inhibits Trypsin Activity

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent EP3851517A1, granting RIKEN exclusive rights in 34 designated member states to a composition containing Paraprevotella bacterium for inhibiting trypsin activity. The composition contains the bacterium as the active ingredient and covers therapeutic and industrial applications of the trypsin inhibitor.

What changed

EPO published patent EP3851517A1 granting RIKEN exclusive rights to a composition containing Paraprevotella bacterium as an active ingredient for inhibiting trypsin activity. The patent names six inventors and covers applications in multiple European designated states including Germany, France, United Kingdom, Italy, Spain, and 28 others.

Affected parties include manufacturers developing enzyme inhibitors, pharmaceutical companies researching digestive disorders, and biotechnology firms working with protease-related applications. Any parties considering research or commercial development involving trypsin inhibition using Paraprevotella-based compositions should evaluate potential licensing needs or design-around strategies to avoid infringement.

What to do next

  1. Monitor for licensing opportunities
  2. Assess freedom-to-operate if developing trypsin inhibitors
  3. Review patent claims for scope of protection

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

COMPOSITION FOR INHIBITING TRYPSIN ACTIVITY, CONTAINING, AS ACTIVE INGREDIENT, BACTERIUM BELONGING TO GENUS PARAPREVOTELLA

Publication EP3851517A1 Kind: A1 Apr 01, 2026

Applicants

RIKEN

Inventors

HONDA Kenya, NARUSHIMA Seiko, WATANABE Eiichiro, OHARA Osamu, KAWASHIMA Yusuke, LI Youxian

IPC Classifications

C12N 1/00 20060101AFI20220511BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Composition for inhibiting trypsin activity Paraprevotella bacterium as active ingredient

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3851517A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers Investors
Industry sector
3254.1 Biotechnology
Activity scope
Patent publication Intellectual property grant Biotech composition
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.